Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation

BACKGROUND: In this phase 2 study, we evaluated the efficacy and safety of oral gepotidacin, a novel triazaacenaphthylene bacterial type II topoisomerase inhibitor, for the treatment of uncomplicated urogenital gonorrhea. METHODS: Adult participants with suspected urogenital gonorrhea were enrolled...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Stephanie N, Morris, David H, Avery, Ann K, Workowski, Kimberly A, Batteiger, Byron E, Tiffany, Courtney A, Perry, Caroline R, Raychaudhuri, Aparna, Scangarella-Oman, Nicole E, Hossain, Mohammad, Dumont, Etienne F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Articles and Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070052/
https://www.ncbi.nlm.nih.gov/pubmed/29617982
http://dx.doi.org/10.1093/cid/ciy145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070052/
https://www.ncbi.nlm.nih.gov/pubmed/29617982
http://dx.doi.org/10.1093/cid/ciy145

Ejemplares similares